Skip to main content
Erschienen in: Journal of Clinical Immunology 8/2014

01.11.2014 | Original Research

Interstitial Lung Disease with Multiple Microgranulomas in Chronic Granulomatous Disease

verfasst von: Toshinao Kawai, Nobuyuki Watanabe, Midori Yokoyama, Yumiko Nakazawa, Fumihiro Goto, Toru Uchiyama, Masataka Higuchi, Takanobu Maekawa, Eiichiro Tamura, Satoshi Nagasaka, Masayuki Hojo, Masafumi Onodera

Erschienen in: Journal of Clinical Immunology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Chronic granulomatous disease (CGD) is a primary immunodeficiency disease that is characterized by susceptibility to bacterial and fungal infections. CGD patients also suffer from immune regulatory disorders, such as CGD-associated bowel inflammation with granuloma, which could be caused by excessive inflammation without demonstrable infection.

Purpose

We investigated the clinical manifestation of interstitial lung disease (ILD) resulting from excessive inflammation in X-linked CGD patients.

Methods

Pulmonary CT images and testing of serum KL-6 levels were performed to assess ILD in the patients. For this study, patients with pulmonary lesions due to demonstrable infections were excluded from among ILD patients.

Results

Among 33 CGD patients, four developed ILD; they had increased reticulo-nodular opacities on CT images and elevated serum KL-6 levels. Histopathological examinations revealed multiple homogeneous microgranulomas in the lesions of inflammatory cell infiltration. Mononuclear cells obtained from their pulmonary lesions produced higher amounts of inflammatory cytokines than the peripheral blood mononuclear cells of CGD patients, suggesting that the only infiltrating cells in the pulmonary lesions were activated and produced large amounts of inflammatory cytokines in ILD patients. Interestingly, an anti-inflammatory drug, such as a corticosteroid or thalidomide, but not anti-bacterial or anti-fungal drugs, improved CT image findings and reduced their KL-6 levels.

Conclusions

CGD patients’ daily exposures to inhaled antigens may induce excessive reactions with the production of inflammatory cytokines leading to the development of ILD with multiple microgranulomas, which could be due to an inadequate production of reactive oxygen species in CGD.
Literatur
1.
Zurück zum Zitat Kang EM, Marciano BE, DeRavin S, Zarember KA, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2011;127(6):1319–26.PubMedCentralPubMedCrossRef Kang EM, Marciano BE, DeRavin S, Zarember KA, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2011;127(6):1319–26.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Kawai T, Kusakabe H, Seki A, Kobayashi S, Onodera M. Osteomyelitis due to trimethoprim/sulfamethoxazole-resistant Edwardsiella tarda infection in a patient with X-linked chronic granulomatous disease. Infection. 2011;39(2):171–3.PubMedCrossRef Kawai T, Kusakabe H, Seki A, Kobayashi S, Onodera M. Osteomyelitis due to trimethoprim/sulfamethoxazole-resistant Edwardsiella tarda infection in a patient with X-linked chronic granulomatous disease. Infection. 2011;39(2):171–3.PubMedCrossRef
3.
Zurück zum Zitat Kobayashi S, Murayama S, Takanashi S, Takahashi K, Miyatsuka S, Fujita T, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr. 2008;167(12):1389–94.PubMedCrossRef Kobayashi S, Murayama S, Takanashi S, Takahashi K, Miyatsuka S, Fujita T, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr. 2008;167(12):1389–94.PubMedCrossRef
4.
5.
Zurück zum Zitat De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122(6):1097–103.PubMedCentralPubMedCrossRef De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122(6):1097–103.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 2010;107(7):3030–3.PubMedCentralPubMedCrossRef van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 2010;107(7):3030–3.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Kawai T, Watanabe N, Yokoyama M, Arai K, Oana S, Harayama S, et al. Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease. Clin Immunol. 2013;147(2):122–8.PubMedCrossRef Kawai T, Watanabe N, Yokoyama M, Arai K, Oana S, Harayama S, et al. Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease. Clin Immunol. 2013;147(2):122–8.PubMedCrossRef
8.
Zurück zum Zitat Fernandez-Boyanapalli R, Frasch SC, Riches DW, Vandivier RW, Henson PM, Bratton DL. PPARgamma activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood. 2010;116(22):4512–22.PubMedCentralPubMedCrossRef Fernandez-Boyanapalli R, Frasch SC, Riches DW, Vandivier RW, Henson PM, Bratton DL. PPARgamma activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood. 2010;116(22):4512–22.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008;140(3):255–66.PubMedCrossRef Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008;140(3):255–66.PubMedCrossRef
10.
Zurück zum Zitat Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;51(12):1429–34.CrossRef Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;51(12):1429–34.CrossRef
11.
Zurück zum Zitat Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96(1):68–73.PubMedCrossRef Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96(1):68–73.PubMedCrossRef
12.
Zurück zum Zitat Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46(6):878–85.PubMedCrossRef Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46(6):878–85.PubMedCrossRef
13.
Zurück zum Zitat Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1–>3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008;46(3):1009–13.PubMedCentralPubMedCrossRef Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1–>3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008;46(3):1009–13.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Meissner F, Seger RA, Moshous D, Fischer A, Reichenbach J, Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood. 2010;116(9):1570–3.PubMedCentralPubMedCrossRef Meissner F, Seger RA, Moshous D, Fischer A, Reichenbach J, Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood. 2010;116(9):1570–3.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Bogaert P, Tournoy KG, Naessens T, Grooten J. Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma. Am J Pathol. 2009;174(1):3–13.PubMedCentralPubMedCrossRef Bogaert P, Tournoy KG, Naessens T, Grooten J. Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma. Am J Pathol. 2009;174(1):3–13.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Khaldi H, Marchand-Adam S, Kannengiesser C, Fabre A, Debray MP, Danel C, et al. Diffuse interstitial pneumonia and pulmonary hypertension: a novel manifestation of chronic granulomatous disease. Eur Respir J. 2009;33(6):1498–502.PubMedCrossRef Khaldi H, Marchand-Adam S, Kannengiesser C, Fabre A, Debray MP, Danel C, et al. Diffuse interstitial pneumonia and pulmonary hypertension: a novel manifestation of chronic granulomatous disease. Eur Respir J. 2009;33(6):1498–502.PubMedCrossRef
17.
Zurück zum Zitat Shah A. Aspergillus-associated hypersensitivity respiratory disorders. Indian J Chest Dis Allied Sci. 2008;50(1):117–28.PubMed Shah A. Aspergillus-associated hypersensitivity respiratory disorders. Indian J Chest Dis Allied Sci. 2008;50(1):117–28.PubMed
18.
Zurück zum Zitat Van Hoeyveld E, Dupont L, Bossuyt X. Quantification of IgG antibodies to Aspergillus fumigatus and pigeon antigens by ImmunoCAP technology: an alternative to the precipitation technique? Clin Chem. 2006;52(9):1785–93.PubMedCrossRef Van Hoeyveld E, Dupont L, Bossuyt X. Quantification of IgG antibodies to Aspergillus fumigatus and pigeon antigens by ImmunoCAP technology: an alternative to the precipitation technique? Clin Chem. 2006;52(9):1785–93.PubMedCrossRef
19.
Zurück zum Zitat Lacasse Y, Selman M, Costabel U, Dalphin JC, Morell F, Erkinjuntti-Pekkanen R, et al. Classification of hypersensitivity pneumonitis: a hypothesis. Int Arch Allergy Immunol. 2009;149(2):161–6.PubMedCrossRef Lacasse Y, Selman M, Costabel U, Dalphin JC, Morell F, Erkinjuntti-Pekkanen R, et al. Classification of hypersensitivity pneumonitis: a hypothesis. Int Arch Allergy Immunol. 2009;149(2):161–6.PubMedCrossRef
20.
Zurück zum Zitat Buchvald F, Petersen BL, Damgaard K, Deterding R, Langston C, Fan LL, et al. Frequency, treatment, and functional outcome in children with hypersensitivity pneumonitis. Pediatr Pulmonol. 2011;46(11):1098–107.PubMedCrossRef Buchvald F, Petersen BL, Damgaard K, Deterding R, Langston C, Fan LL, et al. Frequency, treatment, and functional outcome in children with hypersensitivity pneumonitis. Pediatr Pulmonol. 2011;46(11):1098–107.PubMedCrossRef
21.
Zurück zum Zitat Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876):674–7.PubMedCentralPubMedCrossRef Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876):674–7.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, Feminella J, et al. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One. 2010;5(3):e9631.PubMedCentralPubMedCrossRef Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, Feminella J, et al. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One. 2010;5(3):e9631.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol. 2001;1(4):625–35.PubMedCrossRef Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol. 2001;1(4):625–35.PubMedCrossRef
24.
Zurück zum Zitat Olsson S, Sundler R. The macrophage beta-glucan receptor mediates arachidonate release induced by zymosan: essential role for Src family kinases. Mol Immunol. 2007;44(7):1509–15.PubMedCrossRef Olsson S, Sundler R. The macrophage beta-glucan receptor mediates arachidonate release induced by zymosan: essential role for Src family kinases. Mol Immunol. 2007;44(7):1509–15.PubMedCrossRef
25.
Zurück zum Zitat Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O’Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462–8.PubMedCrossRef Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O’Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462–8.PubMedCrossRef
26.
Zurück zum Zitat Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968–77.PubMedCrossRef Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968–77.PubMedCrossRef
27.
Zurück zum Zitat Meierhofer C, Wiedermann CJ. New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Dev. 2003;6(1):92–9. Meierhofer C, Wiedermann CJ. New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Dev. 2003;6(1):92–9.
28.
Zurück zum Zitat Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am J Gastroenterol. 2009;104(1):117–24.PubMedCrossRef Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am J Gastroenterol. 2009;104(1):117–24.PubMedCrossRef
29.
Zurück zum Zitat Keller M, Sollberger G, Beer HD. Thalidomide inhibits activation of caspase-1. J Immunol. 2009;183(9):5593–9.PubMedCrossRef Keller M, Sollberger G, Beer HD. Thalidomide inhibits activation of caspase-1. J Immunol. 2009;183(9):5593–9.PubMedCrossRef
30.
Zurück zum Zitat Eski M, Sahin I, Sengezer M, Serdar M, Ifran A. Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: is it a new drug for modulation of systemic inflammatory response. Burns. 2008;34(1):104–8.PubMedCrossRef Eski M, Sahin I, Sengezer M, Serdar M, Ifran A. Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: is it a new drug for modulation of systemic inflammatory response. Burns. 2008;34(1):104–8.PubMedCrossRef
31.
Zurück zum Zitat Yasui K, Yashiro M, Tsuge M, Manki A, Takemoto K, Yamamoto M, et al. Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis Rheum. 2010;62(1):250–7.PubMedCrossRef Yasui K, Yashiro M, Tsuge M, Manki A, Takemoto K, Yamamoto M, et al. Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. Arthritis Rheum. 2010;62(1):250–7.PubMedCrossRef
Metadaten
Titel
Interstitial Lung Disease with Multiple Microgranulomas in Chronic Granulomatous Disease
verfasst von
Toshinao Kawai
Nobuyuki Watanabe
Midori Yokoyama
Yumiko Nakazawa
Fumihiro Goto
Toru Uchiyama
Masataka Higuchi
Takanobu Maekawa
Eiichiro Tamura
Satoshi Nagasaka
Masayuki Hojo
Masafumi Onodera
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 8/2014
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-014-0089-1

Weitere Artikel der Ausgabe 8/2014

Journal of Clinical Immunology 8/2014 Zur Ausgabe

Announcement

Announcement

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.